Alector (ALEC) holds steady despite trial failures, pivoting to ABC platform and Roche deal extending cash to 2029.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results